In ovarian cancer, such mutations have been observed after progression on a PARP inhibitor for germline BRCA1, RAD51C and RAD51D mutations 11, 12, as well as in a case of somatic BRCA1 mutation 11. Here, PARP1 is linked to ovarian carcinoma.